LTIP et plan d’options sur actions
Attribution d'options sur actions dans le cadre du programme d'options sur actions et attributions dans le cadre du plan d'intéressement à long terme
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, 14 mars 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces that on March 14, 2024, it granted share options ("Share Options") under the Share Option Scheme adopted by HUTCHMED in 2015 (the "Share Option Scheme") and awards ("LTIP Awards") under the Long Term Incentive Plan adopted by HUTCHMED in 2015 ("LTIP").
Aimed at attracting and retaining top talent, the Remuneration Committee of HUTCHMED appointed an independent advisor to conduct compensation benchmarking research on a selected peer group of companies. As a result of this the Remuneration Committee has comprehensively reviewed the compensation and share-based incentives policies of HUTCHMED and its subsidiaries (the "Group") and established an attractive policy to ensure the Group is able to recruit and retain top talent. In line with this review HUTCHMED has decided to make the following grant of Share Options and LTIP Awards.
1. Performance Related Share Options
HUTCHMED granted Share Options subject to the Performance Targets (defined below) under its Share Option Scheme to Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer), being a person discharging managerial responsibility ("PDMR") under the UK Market Abuse Regulation to subscribe for a total of 1,359,561 ordinary shares with par value US$0.10 each in the share capital of the Company ("Ordinary Shares") subject to the acceptance of the grantee. Details of such Share Options granted are as follows:
Date d'octroi | : | 13 mars 2024
|
Prix d'exercice des options sur actions attribuées | : | HK$28.35 per Ordinary Share
|
Nombre d'options sur actions attribuées | : | 1,359,561 XNUMX XNUMX Actions Ordinaires
|
Cours de clôture du marché des actions ordinaires à HKEX à la date d'attribution
| : | HK$28.35 per Ordinary Share
|
Période d'exercice des options sur actions | : | Du 13 mars 2024 au 12 mars 2034
|
Période d'acquisition des options sur actions | : | Vesting will occur two business days after the date of announcement of the annual results of the Company for the financial year ending December 31, 2025 (the "2025 Results Announcement").
|
Objectifs de performance | : | The exercise of the share options is conditional upon the fulfilment of certain performance targets relating to the Group over the financial years 2023 to 2025 (the "Performance Targets"). The number of share options to be exercisable will be determined on the date of 2025 Results Announcement. The Performance Targets have been determined by the Board and specified in the grant letter of Dr Su. To the extent that the Performance Targets have not been met, the relevant number of share options granted to Dr Su will lapse.
|
Mécanisme de récupération | : | The share options may be subject to the clawback policy of the Company enabling the Company to recover incentive-based compensation paid to covered executive officers in the event of mis-statement of the financial statements of the Company resulting from material non-compliance with financial reporting requirements. |
After the above grant of Share Options, the number of Share Options available for future grant under the scheme mandate of the Share Option Scheme is 11,678,982.
2. Non-performance-related LTIP Award ("Non-performance LTIP Award") - a one-off cash amount was granted to each grantee and will be used by the trustee administering the LTIP (the "Trustee") to purchase Ordinary Shares in HUTCHMED which will be subject to a vesting schedule over four years. HUTCHMED granted the following Non-performance LTIP Awards to the following Executive Director, being a PDMR under the UK Market Abuse Regulation:
Titulaire du prix |
| Cash amount for the Non- Attributions de performance RILT |
|
|
|
Dr Weiguo Su (directeur exécutif, directeur général et directeur scientifique) |
| US $ 500,000 |
The non-performance-related LTIP Award was granted to Dr Su in recognition of his contribution to the Company in his dual role as Chief Executive Officer and Chief Scientific Officer.
Another employee of the Group has simultaneously been granted non-performance related LTIP Awards.
The notification in respect of share options granted to Dr Su in accordance with the requirements of the UK Market Abuse Regulation is set out below.
Dr Weiguo Su
1 | Détails de la personne exerçant des responsabilités de direction / personne étroitement associée | |||||||
a) |
Nom |
Dr Weiguo Su
| ||||||
2 | Motif de la notification | |||||||
a) |
Poste/statut |
Directeur exécutif, président-directeur général et directeur scientifique
| ||||||
b) |
Notification initiale/Modification
|
Notification initiale
| ||||||
3 | Coordonnées de l'émetteur, du participant au marché des quotas d'émission, de la plate-forme d'enchères, du commissaire-priseur ou du contrôleur des enchères | |||||||
a) |
Nom
|
HUTCHMED (Chine) Limited | ||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||
4 | Détails de la (des) transaction (s): section à répéter pour (i) chaque type d'instrument; (ii) chaque type de transaction; (iii) chaque date; et (iv) chaque lieu où des transactions ont été effectuées | |||||||
a) |
Description de l'instrument financier, type d'instrument
Code d'identification |
Share option over Ordinary Shares of US$0.10
Share option over Ordinary Share with DI ISIN: KYG4672N1016 | ||||||
b) |
Nature de la transaction
|
Grant of options in respect of 1,359,561 Ordinary Shares under the Share Option Scheme.
The exercise of the share options is conditional upon the fulfilment of certain performance targets relating to the Group over the financial years 2023 to 2025 (the "Performance Targets"). The number of share options to be exercisable will be determined on the date of 2025 Results Announcement. The Performance Targets have been determined by the Board and specified in the grant letter of Dr Su. To the extent that the Performance Targets have not been met, the relevant number of share options granted to Dr Su will lapse.
| ||||||
c) |
Prix(s) et volume(s) |
| ||||||
d) |
Informations agrégées
|
N/D | ||||||
e) |
Date de la transaction |
2024-3-13
| ||||||
f) |
Lieu de la transaction |
En dehors d'une plate-forme de négociation
|
À propos d'HUTCHMED
HUTCHMED (Nasdaq/AIM:?HCM; HKEX:?13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/?immunology. Since inception, it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S.. For more information, please visit: www.hutch?med.com or follow us on LinkedIn.
Avant-Rechercher des déclarations
Cette annonce contient des déclarations prospectives au sens des dispositions de la « sphère de sécurité » de la loi américaine Private Securities Litigation Reform Act de 1995. Les déclarations prospectives impliquent des risques et des incertitudes. Les investisseurs existants et potentiels sont avertis de ne pas se fier indûment à ces déclarations prospectives, qui ne sont valables qu'à la date des présentes. Pour une discussion plus approfondie de ces risques et d'autres, voir les documents déposés par HUTCHMED auprès de la Securities and Exchange Commission des États-Unis, sur AIM et sur HKEX. HUTCHMED n'assume aucune obligation de mettre à jour ou de réviser les informations contenues dans cette annonce, que ce soit à la suite de nouvelles informations, d'événements ou de circonstances futurs ou autrement.
CONTACTS
Demandes des investisseurs | +852 2121 8200 / [email protected] |
Demandes des médias |
|
Ben Atwell/Alex Shaw, FTI Consulting | +44 20 3727 1030 / + 44 7771 913 902 (Portable) / +44 7779 545 055 (Portable) | [email protected] |
Zhou Yi, Brunswick | +852 9783 6894 (Mobile) |
Conseiller désigné | |
Atholl Tweedie / Freddy Crossley / Daphné Zhang, Panmure Gordon | +44 (20) 7886 2500 |
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.